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Abstract
Background: Bisphosphonates (BPs) are potent antiresorptive agents used to treat osteoporosis and the
complications associated with malignant bone metastasis. The aim of this study was to evaluate the incidence of
bisphosphonate-related osteonecrosis of the jaw (BRONJ) using the Japanese Adverse Drug Event Report (JADER)
database. In particular, we focused on the time-to-onset profile of BRONJ.
Findings: We analyzed reports of BRONJ in the JADER database and calculated the reporting odds ratio (ROR) of
BPs potentially associated with BRONJ. We applied the weibull shape parameter to time-to-event data in JADER.
The drugs selected for this investigation were seven BPs approved in Japan (alendronate [intraveneous, I.V.],
pamidronate, and zoledronate as I.V. BPs; and alendronate (oral), etidronate, minodronate, and risedronate as oral
BPs). We analyzed reports of BRONJ events associated with BPs in the JADER database from April 2004 to
November 2014. The median value of BRONJ cases caused by alendronate (I.V.), pamidronate, zoledronate,
alendronate (oral), etidronate, minodronate, and risedronate were 1342, 812, 486, 863, 1461, 432, and 730 days,
respectively. The lower 95 % confidence interval of the Weibull-shape parameter β for I.V. BPs (pamidronate and
zoledronate) exceeded 1. The risk of BRONJ with I.V. BPs increased over time.
Conclusion: Thus, the incidence of BRONJ with BP treatment should be closely monitored for a 3-year period.
Further studies are required to draw conclusions, and we believe that this information about BRONJ induced by BPs
will prove beneficial to patients and pharmacists.
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Findings
Background
Bisphosphonates (BPs) are widely used for the treat-
ment of osteoporosis and complications associated
with malignant bone metastasis [1]. Bisphosphonate-
related osteonecrosis of the jaw (BRONJ) has been
recognized as an uncommon but severe adverse
event that affects the quality of life of patients. The
risk of BRONJ depends on the type of BPs and the
duration of exposure, and the majority of BRONJ
patients experience the complication following sim-
ple dentoalveolar surgery [2, 3]. According to the pos-
ition paper on BRONJ from American Association of Oral
and Maxillofacial Surgeons (AAOMS), patients receiving
oral BPs are at a risk of BRONJ, but to a much lesser
degree than those treated with I.V. BPs. The risk of oral
BPs may be associated with longer treatment durations,
such as over 3–4 years [2, 3].
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Since BRONJ is a rare adverse event [4], epidemiologic
research on this condition is difficult. The regulatory
authority in Japan, the Pharmaceuticals and Medical
Devices Agency (PMDA), has released the spontaneous
reporting system (SRS) of the Japanese Adverse Drug
Event Report (JADER) database. The JADER database is
the largest and best-known database, and it reflects the
realities of clinical practice. Therefore, JADER has been
recognized as one of the primary tools for pharmacovigi-
lance assessments [5]. Analysis of time-to-onset data has
been proposed as a method to detect signals for adverse
drug reactions (ADRs) in SRS [6–8]. As far as we
know, analyses of the time-to-onset for BRONJ using
the JADER database are rare. The aim of this study
was to assess the time-to-onset data of BRONJ by BP
treatment.
Methods
Adverse events recorded from April 2004 to November
2014 in the JADER database were downloaded from the
PMDA website (http://www.pmda.go.jp). The database
consists of 4 data tables: patient demographic informa-
tion (demo), drug information (drug), adverse events
(reac), and primary disease (hist). The adverse events in
“reac” are coded according to the terminology preferred
by the Medical Dictionary for Regulatory Activities
(MedDRA) [9]. “Drug” file (drug information) includes
role codes assigned to each drug: suspected drug
(higiyaku in Japanese), interacting drug (sougosayou
in Japanese), and concomitant drug (heiyouyaku in
Japanese). Suspected drugs were extracted and ana-
lyzed in this study. The drugs selected for this investiga-
tion were seven BPs approved in Japan (alendronate
[intraveneous, I.V.], pamidronate, and zoledronate as I.V.
BPs; alendronate (oral), etidronate, minodronate, and rise-
dronate as oral BPs). BPs were grouped by dosages and
each BP was stratified by dosages: pamidoronate (30–
45 mg), pamidoronate (90 mg), zoledronate (4 mg), alen-
dronate (5 mg), alendronate (35 mg), risedronate (2.5 mg),
and risedronate (17.5 mg). We used the preferred term
“osteonecrosis of jaw” to match cases of BRONJ accord-
ing to MedDRA. To detect the incidence of BRONJ, we
calculated the reporting odds ratio (ROR), which is an
established parameter for pharmacovigilance research,
using a disproportionality analysis [10]. “Cases” were de-
fined as patients who reported BRONJ, while “non-cases”
consisted of patients associated with all other reports. The
ROR is the ratio of the odds of reporting adverse events
versus all other events associated with BPs compared to
the reporting odds for all other drugs present in the
database. To compare the “cases” and “non-cases,” we cal-
culated the RORs as (a:c)/(b:d) (Fig. 1). RORs were
expressed as point estimates with a 95 % confidence inter-
val (CI). For signal detection, general qualitative judg-
ments were used. The detection of a signal was dependent
on the signal indices exceeding a predefined threshold.
ROR values <1 indicated no exposure-event association,
and estimates >1 indicated exposure-event safety signals.
Safety signals are considered significant when the ROR
estimates and the lower limits of the corresponding 95 %
CI are >1 [10].
The median of the data, quartiles, and the Weibull
shape parameter (WSP) were utilized in evaluations of
the time-to-onset data for BRONJ. Time-to-onset from
the JADER database was calculated from the beginning
of the time of a subject’s first prescription to the occur-
rence of the adverse events. Different BPs were not
administered at the same time. For duplicate entries of
the same BPs in the same case, we adopted the most re-
cent BP entry in order to identify the beginning of the
time of a subject’s first prescription. The WSP test is
used for statistical analysis of time-to-onset data and can
describe the non-constant rate of incidence of ADRs
(i.e., the risk of increase or decrease over time) [7, 8].
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Fig. 1 Two by two table used for the calculation of reporting odds ratios
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The shape parameter β of the Weibull distribution indi-
cated that the hazard without a reference population;
when β is equal to 1, the hazard is estimated to be
constant over time. If β is greater than 1 and the 95 %
CI of β excluded the value 1, the hazard was considered
to increase over time.
All data analyses were performed by JMP 11.0 (SAS
Institute Inc., Cary, NC, USA).
Results
The JADER database contains 338,224 reports from
April 2004 to November 2014. The database contains
4,128,716 combinations of drugs and ADRs. After
extracting the combinations completed within the begin-
ning date of the treatment and the occurrence date of
adverse events, a total of 1,777,925 combinations were
analyzed. The number of reports with “osteonecrosis of
jaw” was 3,027. The RORs (95 % CI) of alendronate (I.V.),
pamidronate, zoledronate, alendronate (oral), etidronate,
minodronate, and risedronate were 43.7 (22.1–86.4), 315.0
(256.3–387.0), 346.2 (308.2–388.8), 92.3 (81.4–104.5),
160.3 (83.5–307.7), 17.3 (12.7–23.5), and 48.4 (40.3–58.0),
respectively (Table 1). The number of cases for zoledro-
nate in males and females were 301 and 474, respectively
(Table 1). The number of cases for alendronate (oral) in
males and females were 22 and 379, respectively.
The RORs stratified by dosages are summarized in
Table 2. The complete report with dosage amount was
analyzed. The RORs for pamidoronate (30–45 mg),
pamidoronate (90 mg), zoledronate (4 mg), alendronate
(5 mg), alendronate (35 mg), risedronate (2.5 mg), and
risedronate (17.5 mg) were 159.4 (107.5–236.2), 298.0
(204.8–433.6), 226.6 (198.8–258.3), 91.7 (75.6–111.3),
68.2 (57.8–80.4), 42.5 (32.9–54.8), and 34.9 (24.3–50.1),
respectively.
The number of case reports for alendronate (I.V.),
pamidronate, zoledronate, alendronate (oral), etidronate,
minodronate, and risedronate was 6, 118, 408, 196, 9,
32, and 65, respectively (Table 3). The median values for
BRONJ caused by alendronate (I.V.), pamidronate,
zoledronate, alendronate (oral), etidronate, minodronate,
and risedronate were 1342, 812, 486, 863, 1461, 432, and
730 days, respectively (Table 3). The Weibull distribu-
tion parameters for each BP are summarized in Table 3.
The lower 95 % CI of β for both I.V. BPs (pamidronate
and zoledronate) and alendronate (oral) exceeded 1, but
those for other BPs did not exceed 1 (Table 3). The me-
dian values for BRONJ caused by pamidronate (30–45 mg),
pamidoronate (90 mg), zoledronate (4 mg), alendronate
(5 mg), alendronate (35 mg), risedronate (2.5 mg), and
risedronate (17.5 mg) were 844, 783, 488, 1263, 680, 1081,
and 112 days, respectively (Table 4). The lower 95 % CI of
Table 1 Number of reports and reporting odds ratio of BRONJ stratified by gender
Dosage form Drug name Case Non-case Total Reporting odds ratio (95 % CI)
Intravenous Alendronate (I.V.) 10 48 58 43.7 (22.1 − 86.4)
Male 2 8 10 52.1 (11.1 − 245.7)
Famale 8 40 48 41.9 (19.6 − 89.6)
Pamidronate 223 171 394 315.0 (256.3 − 387.0)
Male 30 35 65 181.9 (111.4 − 297.0)
Famale 186 128 314 341.9 (271.4 − 430.8)
Zoledronate 809 972 1,781 346.2 (308.2 − 388.8)
Male 301 436 737 176.5 (150.9 − 206.4)
Famale 474 514 988 271.4 (236.5 − 311.4)
Oral Alendronate (oral) 414 1,252 1,666 92.3 (81.4 − 104.5)
Male 22 146 168 31.8 (20.3 − 49.9)
Famale 379 1,096 1,475 93.8 (82.4 − 106.8)
Etidronate 16 21 37 160.3 (83.5 − 307.7)
Male 3 4 7 156.5 (35.0 − 699.9)
Famale 13 17 30 160.6 (77.9 − 331.1)
Minodronate 45 558 603 17.3 (12.7 − 23.5)
Male 4 49 53 17.0 (6.1 − 47.3)
Famale 41 483 524 18.1 (13.1 − 25.0)
Risedronate 152 721 873 48.4 (40.3 − 58.0)
Male 18 81 99 46.8 (28.0 − 78.2)
Famale 131 614 745 48.3 (39.7 − 58.7)
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β for pamidronate (30–45 mg), pamidoronate (90 mg),
zoledronate (4 mg), alendronate (5 mg), and risedronate
(2.5 mg) exceeded 1, but those for alendronate (35 mg) and
risedronate (17.5 mg) did not exceed 1 (Table 4).
Figures 2 and 3 show the histogram of the number
of cases of BRONJ between 0 day to 4,000 days. The
interval of the quartile points was very large in all
BPs, but the lower quartile point was over 150 days
for all BPs except risedronate (17.5 mg).
Discussion
The risks of BRONJ related to antiresorptive therapy are
well recognized by clinicians [11]. In patients receiving
drugs via the I.V. route, the prevalence of BRONJ was
1–10 %, while the prevalence was 0.00007–0.04 % in
those using the oral route [3]. The I.V. route of adminis-
tration results in a greater drug exposure than the oral
route [2, 3]. Zoledronate is more potent than pami-
dronate, while pamidronate is more potent than oral
BPs [2, 3]. In in vitro analysis, zoledronate was the
most potent inhibitor of farnesyl pyrophosphate
synthase, followed by risedronate, alendronate, and
pamidronate [12]. The inhibition of farnesyl
pyrophosphate is associated with effectiveness in
suppressing bone turnover in vivo [13]. Several re-
ports have suggested that the pathogenesis of BRONJ
is partially associated with osteonecrosis by suppres-
sion of bone turnover. In our study, the number of
reported cases of BRONJ increased after administra-
tion of BPs. The obtained RORs for all of the BPs
and their lower limits of 95 % CI were >1. The
RORs for zoledronate and pamidronate were higher
than those for the oral BPs, and the ROR for zole-
dronate was higher than that for alendronate (I.V.).
The results obtained in this study were reasonable in
the context of those reported in the literature from
the JADER database.
The risk of developing BRONJ associated with oral
BPs increases when the duration of therapy exceeds 3–4
years [2, 3]. The median duration of BP exposure for
patients with BRONJ and BRONJ-like features was
4.4 years [14, 15]. Yoneda et al. demonstrated that the
incidence of BRONJ begins to increase 1 year after intra-
venous BP and 2–3 years after oral BP administration
[11]. In Japan, the mean duration of administration until
onset of BRONJ was 23.6 months (2.0 years) for I.V. BPs
and 33.3 months (2.8 years) for oral BPs [16]. The median
time-to-onset of BRONJ for BPs, zoledronate, pamidro-
nate, and alendronate (oral) was 486 (1.3 years), 812
(2.2 years), and 863 days (2.4 years), respectively. BRONJ
with BPs treatment should be closely monitored within
3 years. The results of the shape parameter of the Weibull
distribution indicated that the risk of BRONJ with the oral
BPs, minodronate and risedronate, is almost constant.
The number of case reports for analysis of etidronate,
minodronate, and risedronate were less than 100 (Table 3).
Owing to the low frequency of disease, studies with small
samples need to be interpreted cautiously. However, the
risk of BRONJ with I.V. BPs, pamidronate and zoledro-
nate, increased over time. This is likely because of the
strong exposure to I.V. BPs among the patients. More
than half of the reports on BRONJ with I.V. BP treatment
were recorded within 3 years (Figs. 2 and 3). Our results
indicate the importance of comparing drug safety profiles
using post-marketing real-world data.
Gender was reported as a demographic and systematic
risk factor for BRONJ [17]. BRONJ is rare in male patients
with osteoporosis [18]. For oral BPs, the number of re-
ports of BRONJ in males was lower than that in females
(Table 1). Since zoledronate was used to prevent skeletal
fractures in patients with multiple myeloma and prostate
cancer, the number of reports for zoledronate in males
might be similar to that in females (Table 1). Cumulative
BP exposure has been proposed as an important risk
Table 2 Number of reports and reporting odds ratio of BRONJ stratified by formulations and dosages
Dosage form Drug name Case Non-case Total Reporting odds ratio (95 % CI)
Intravenous Pamidronate 223 171 394 315.0 (256.3 − 387.0)
30 mg − 45 mga 44 59 103 159.4 (107.5 − 236.2)
90 mga 66 48 114 298.0 (204.8 − 433.6)
Zoledronate 809 972 1,781 346.2 (308.2 − 388.8)
4 mga 494 651 1,145 226.6 (198.8 − 258.3)
Oral Arendronate (oral) 414 1,252 1,666 92.3 (81.4 − 104.5)
5 mga 155 388 543 91.7 (75.6 − 111.3)
35 mga 202 702 904 68.2 (57.8 − 80.4)
Risedronate 152 721 873 48.4 (40.3 − 58.0)
2.5 mga 73 374 447 42.5 (32.9 − 54.8)
17.5 mga 35 213 248 34.9 (24.3 − 50.1)
aReports completed with dosage amount were analyzed
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Table 3 Time-to-onset analysis of bisphosphonates








Scale parameter: α Shape parameter: β
α (95 % CI) β (95 % CI)
Intravenous Alendronate (I.V.) 10 (6) 1,342 691 1,701 1267.6 (737.0 − 2125.0) 2.15 (0.96 − 3.83)
Pamidronate 223 (118) 812 567 1,227 934.7 (816.9 − 1066.3) 1.45 (1.26 − 1.64)
Zoledronate 809 (408) 486 274 821 631.5 (586.8 − 678.9) 1.41 (1.30 − 1.52)
Oral Alendronate (oral) 414 (196) 863 432 1,463 1095.4 (970.2 − 1233.8) 1.23 (1.09 − 1.37)
Etidronate 16 (9) 1,461 389 2,068 1390.3 (766.8 − 2442.7) 1.49 (0.74 − 2.63)
Minodronate 45 (32) 432 196 742 629.5 (408.3 − 954.8) 0.90 (0.69 − 1.13)

















Table 4 Time-to-onset analysis of bisphosphonates stratified by formulations and dosages








Scale parameter: α Shape parameter: β
α (95 % CI) β (95 % CI)
Intravenous Pamidronate (30 − 45 mg) 44 (35) 844 658 1,199 775.6 (641.8 − 928.9) 1.98 (1.49 − 2.53)
Pamidronate (90 mg) 66 (48) 783 532 1,041 889.5 (706.1 − 1112.6) 1.35 (1.09 − 1.63)
Zoredronate (4 mg) 494 (355) 488 290 811 634.1 (587.7 − 683.4) 1.46 (1.34 − 1.59)
Oral Arendronate (5 mg) 155 (72) 1,263 757 1,951 1450.5 (1258.1 − 1664.5) 1.77 (1.46 − 2.12)
Arendronate (35 mg) 202 (102) 680 309 1,106 804.9 (663.0 − 972.3) 1.08 (0.91 − 1.25)
Risedronate (2.5 mg) 73 (39) 1,081 495 1,706 1288.6 (1008.4 − 1634.3) 1.41 (1.06 − 1.82)

















factor for the development of BRONJ. There are various
BP formulations and dosages. BPs were initially adminis-
tered orally either once daily (alendronate [5 mg], risedro-
nate [2.5 mg]), once weekly (alendronate [35 mg] and
risedronate [17.5 mg]), and, recently, intravenous formula-
tions (zoledronate [4 mg], pamidoronate [30–45 mg], and
pamidoronate [90 mg]) has been developed. The median
values for BRONJ caused by alendronate (35 mg, 680 days)
were almost half that for alendronate (5 mg, 1263 days)
(Table 4). We believe that the findings of this study will be
of great value to clinicians who administer BPs to patients.
Several observational studies have identified poten-
tial risk factors associated with the development of
BRONJ. Age, gender, cancer diagnosis with or without
osteoporosis, renal dialysis, obesity, and co-administrated
drug were reported as demographic and systematic risk
factors for BRONJ [17]. Dentoalveolar surgeries such as
extraction and dental implant placement are local risk
factors [2, 3]. Corticosteroid use is associated with an in-
creased risk for BRONJ [3]. These covariates should be
confirmed by using further epidemiological studies, such
as case–control or cohort studies.
SRS, such as the JADER database, is subject to various
biases, including over-reporting, under-reporting, miss-
ing data, the exclusion of healthy individuals, the lack of
denominator, and confounding factors [5, 10, 19, 20]. In
the JADER database, some of the numbers of reports
may reflect duplicate reporting due to factors such as
follow-up reports received on a case or different persons
reporting on the same patient case. It is recommended
that identify duplicate reports of the same patient that
come from different reporting sources and excluded
these from the analysis. However, there is no key code
for the identification of duplicate reports in the JADER
database. Further studies are necessary to determine
more precisely. Because of these limitations, dispropor-
tionality measures (ROR) do not allow for risk quantifi-
cation. Rather, RORs offer a rough indication of signal
strength and are only relevant to the hypothesis. In
absolute terms, the ROR indicates an increased risk of
adverse event reporting, and not a risk of adverse event
occurrence. Therefore, careful attention must be paid to
the interpretation of the results from the JADER
database.
d)Alendronate (Oral)
(   = 1.23, 95% CI 1.09–1.37) 
e)Etidronate
(   = 1.49, 95% CI 0.74–2.63) 
c)Zoledronate
(   = 1.41, 95% CI 1.30–1.52) 
g)Risedronate
(   = 1.02, 95% CI 0.82–1.24) 
b)Pamidronate
(   = 1.45, 95% CI 1.26–1.64) 
a)Alendronate (Intravenous)
(   = 2.15, 95% CI 0.96–3.83) 
f) Minodronate
(   = 0.90, 95% CI 0.69–1.13) 
Fig. 2 Histogram and Weibull shape parameter of BRONJ for (a) alendronate (Intravenous), (b) pamidronate, (c) zoledronate, (d) alendronate
(oral), (e) etidronate, (f) minodronate and (g) risedronate
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Despite the limitations inherent to SRS, our study
indicated that BRONJ with BP treatment typically oc-
curred within 3 years from the start of the treatment
with BPs. Despite the clinical correlation between BPs
and BRONJ, a definitive causal relationship has yet to be
established [3]. There is no way to predict which individ-
uals taking BPs are at greatest risk of developing BRONJ,
nor is there evidence of prognostic indicators that are
predictive of outcomes. Therefore, clinicians should
comply with guidelines and monitor patients for adverse
BRONJ events. This study was the first to evaluate the
relationship between BP and BRONJ by using the
JADER database. We hope that these data will update
the information available to clinicians and be potentially
useful for improving the management of BRONJ.
Conclusion
This study was the first to evaluate the relationship be-
tween BPs and BRONJ by using the JADER database.
The present analysis demonstrate that the incidence of
BRONJ with BP treatment should be closely monitored
for a 3-year period. WSP was deemed to be a useful tool
for the time-to-onset analysis. We hope that these data
will update the information available to clinicians and be
potentially useful for improving the management of
BRONJ induced by BPs.
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Fig. 3 Histogram and Weibull shape parameter of BRONJ stratified by formulations and dosages for (a) pamidronate (30−45mg), (b) pamidronate
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